Earnings Call InsightsElectroCore outlines 30% revenue growth potential for 2026 as leadership transition advancesMar 19, 2026, 8:02 PM ETelectroCore, Inc. (ECOR) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: electroCore, Inc. (ECOR) Q4 2025 Management View Daniel Goldberger, CEO, announced his decision to retire effective April 1, 2026, following a tenure focused on strengthening the company’s financial position, commercial strategy, and expansion in the VA channel. He stated, "I ...

I'm confident the leadership team will continue building on the progress we've made and drive the company forward in the next phase of growth. It's been an honor to lead this organization and serve you, our shareholders. Thank you for your unwavering support. I look forward to watching electroCore thrive [indiscernible] Now the Chairman, Dr. Errico like to share a few thoughts on strategy and [indiscernible]With that foundation now in place, the Board and I believe this is the right time to begin a leadersh ...

Errico emphasized the clinical foundation supporting electroCore’s non-invasive vagus nerve stimulation (nVNS) platform. He said the company’s flagship gammaCore device is supported by more than 20 peer-reviewed publications and multiple randomized controlled trials, including ACT-one, ACT-two, PRESTO, and PREMIUM, which he said demonstrated statistically significant reductions in migraine and cluster headache frequency, intensity, and duration. Errico noted gammaCore is FDA-cleared for both acute and preve ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached a record $9.2 million, up 31% year-over-year, bringing full year 2025 revenue to $32 million, a 27% increase over 2024 [14][18] - Prescription device revenue increased 23% year-over-year to $26 million, driven by growth in gammaCore and Quell products [14][18] - Net loss for 2025 was $14 million or $1.65 per share, compared to a net loss of $11.9 million or $1.59 per share in 2024 [21][22] Business Line Data and Key Metrics Changes - VA hospital system remains the largest customer, with 200 facilities purchasing gammaCore products, up from 170 a year ago [14][15] - General wellness revenue reached $5.5 million for the full year, a 97% increase compared to 2024, primarily driven by Truvaga sales [15][16] - Truvaga sales increased by 93% from 2024, totaling $5.4 million [16] Market Data and Key Metrics Changes - Approximately 13,400 VA patients received gammaCore devices, representing roughly 2% penetration of the addressable VA headache market [15] - NHS England remains a key channel for international sales, with ongoing efforts to develop infrastructure for reimbursement in other countries [38] Company Strategy and Development Direction - The company is focused on increasing sales within the VA system and expanding into general wellness with the Truvaga product [8][12] - A leadership transition is underway, with Joshua Lev appointed as Interim President and Michael Fox joining as Chief Operating Officer to enhance commercial efforts [5][8] - The company aims to introduce additional wellness offerings and a next-generation mobile application to support recurring revenue opportunities [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for sustained revenue acceleration and long-term value creation [12][23] - The leadership transition is seen as an opportunity to maintain operational momentum while focusing on growth strategies [6][7] - The company expects 2026 revenue to continue growing at approximately 30% [23] Other Important Information - Gross margin improved to 87% compared to 85% in 2024 [18] - Research and development expenses increased to $2.7 million, primarily for gammaCore Emerald and mobile application development [19] Q&A Session Summary Question: Can you discuss the channels for gammaCore and Quell in 2026? - Management highlighted the growth in the VA channel and the addition of commercial leaders to accelerate growth [30][31] Question: What about the OUS channels and specific geographies? - NHS England remains the primary focus for international revenue, with ongoing efforts to develop reimbursement pathways in other countries [35][38] Question: Will Michael Fox focus on the VA business while Joshua handles wellness? - Michael will oversee broader commercial strategies, including VA and other federal systems, while Joshua will manage wellness products [44][45] Question: Any updates on insurance reimbursement coverage? - The company is focused on Kaiser as a key opportunity for broader reimbursement adoption, with plans to leverage success for additional managed care systems [58][59]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached a record $9.2 million, up 31% year-over-year, bringing full year 2025 revenue to $32 million, a 27% increase over 2024 [14][18] - Prescription device revenue increased 23% year-over-year to $26 million, driven by growth in gammaCore and Quell products [14][18] - Net loss for 2025 was $14 million or $1.65 per share, compared to a net loss of $11.9 million or $1.59 per share in 2024 [21][22] Business Line Data and Key Metrics Changes - VA hospital system remains the largest customer, with 200 facilities purchasing gammaCore products, up from 170 a year ago [14][15] - General wellness revenue for Q4 reached $1.4 million, representing 31% year-over-year growth, with full year revenue totaling $5.5 million, a 97% increase compared to 2024 [15][16] Market Data and Key Metrics Changes - Approximately 13,400 VA patients received gammaCore devices, representing roughly 2% penetration of the addressable VA headache market [15] - The company is expanding its VA sales presence by adding internal team members and contracted representatives [15] Company Strategy and Development Direction - The company is focused on increasing sales within covered entities such as the VA system and expanding into general wellness with the Truvaga product [8][12] - A leadership transition is underway, with Joshua Lev appointed as interim president and Michael Fox joining as Chief Operating Officer to enhance commercial efforts [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for sustained revenue acceleration and long-term value creation, emphasizing the importance of operational efficiency [12][23] - The company expects full year 2026 revenue to continue growing at approximately 30%, although detailed guidance is not being issued at this time due to the leadership transition [23] Other Important Information - The company is investing in people, marketing, and product development to accelerate growth while maintaining discipline around operating efficiency [17][23] - The Quell Relief product is expected to launch in the first half of 2026, with revenue from this product considered incremental to existing guidance [52] Q&A Session Summary Question: Can you talk about the channels, VA and DTC for both gammaCore and Quell? - Management highlighted the acceleration in the VA channel and the addition of new commercial leadership to drive growth [30][31] Question: Can you discuss OUS channels and expectations for 2026? - The NHS in England remains a key focus for OUS revenue, with ongoing efforts to develop infrastructure in other countries [34][38] Question: Will Michael focus primarily on the VA business while Joshua handles wellness and ex-VA? - Yes, Michael will focus on commercial growth across various channels, while Joshua will manage wellness products [44][45] Question: Is there any adjustment to VA contracts with the onboarding of Michael? - Current VA contracts are expected to remain unchanged, but opportunities for efficiency improvements may be explored [47] Question: Will there be a de-emphasis on the TAC-STIM product after Dan's departure? - No, there is still a robust pipeline for TAC-STIM, and Michael's experience may help accelerate revenue opportunities [49] Question: Will Quell Relief be sold into VA/DOD channels or general wellness? - Quell Relief is an over-the-counter product expected to launch in the first half of 2026, with revenue considered incremental to guidance [52] Question: What are the updates on insurance reimbursement coverage? - The company has made progress with Kaiser, which is seen as a significant opportunity for broader reimbursement adoption [56][58]

electroCore (NasdaqCM:ECOR) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Speaker5Greetings, and welcome to the electroCore fourth quarter and full year 2025 earnings conference call. At this time, all participants have been placed in a listen-only mode. Please make sure to mute yourself. Question and answer session will follow the formal presentation. A reminder, this conference call is being recorded. Earlier today, electroCore published results for the fourth quarter and full year ended December 31, 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-3454976 (State or other jurisdiction of in ...

Financial Guidance - electroCore, Inc. provided preliminary financial guidance for the three and 12 months ended December 31, 2025[4] - The financial results are based on unaudited information and management estimates, subject to change[6] - The company cautioned that actual results may differ materially from the preliminary estimates provided[8] - Upcoming presentations will include these preliminary financial estimates for investor and analyst discussions[5] Audit and Review - The independent registered public accounting firm has not conducted an audit or review of these preliminary results[6] - The financial information is not deemed "filed" under the Securities Exchange Act of 1934[7] Risk Factors - Investors are advised to refer to the "Risk Factors" section of the Company's Annual Report for potential discrepancies in actual results[8] Forward-Looking Statements - The company has no obligation to publicly release updates on forward-looking statements unless required by law[8] Documentation - The press release and investor presentation are filed as Exhibits 99.1 and 99.2, respectively[11] - The report was signed by Joshua S. Lev, Chief Financial Officer, on January 20, 2026[15]

Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) ("electroCore ...

Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...